The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohorts.
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts / Barr, Paul M; Tedeschi, Alessandra; Wierda, William G; Allan, John N; Ghia, Paolo; Vallisa, Daniele; Jacobs, Ryan; O'Brien, Susan; Grigg, Andrew P; Walker, Patricia; Zhou, Cathy; Ninomoto, Joi; Krigsfeld, Gabriel; Tam, Constantine S. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 28:20(2022), pp. 4385-4391. [10.1158/1078-0432.CCR-22-0504]
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts
Ghia, Paolo
;
2022-01-01
Abstract
The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking and tumor lysis syndrome (TLS) risk category reduction with three cycles of single-agent ibrutinib lead-in before initiation of venetoclax using pooled data from the MRD and FD cohorts.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
